JAZZ

JAZZ

USD

Jazz Pharmaceuticals plc Common Stock (Ireland)

$120.050+1.230 (1.035%)

Reaalajas hind

Healthcare
Biotehnoloogia
Iirimaa

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$118.820

Kõrge

$120.670

Madal

$118.745

Maht

0.34M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

7.4B

Tööstusharu

Biotehnoloogia

Riik

Ireland

Kauplemisstatistika

Keskmine maht

1.20M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $95.49Praegune $120.050Kõrge $148.06

Seotud uudised

PR Newswire

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Vaata rohkem
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
PR Newswire

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present seven abstracts at the American...

Vaata rohkem
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
PR Newswire

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after...

Vaata rohkem
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
PR Newswire

Jazz Pharmaceuticals Completes Acquisition of Chimerix

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc....

Vaata rohkem
Jazz Pharmaceuticals Completes Acquisition of Chimerix
Analyst Upgrades

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $210 Price Target

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals with a Buy and maintains $210 price target.

Vaata rohkem
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $210 Price Target